ProCE Banner Events


Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Join us for this dynamic, case-based, CME/CE/CPE-certified live symposium, in which an expert panel will discuss current recommendations and emerging strategies for treating patients with CLL. Sign up now!

Friday Satellite Symposium on Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, preceding the 65th ASH Annual Meeting and Exposition

This event has expired. No longer available for credits.

Who Should Attend

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL.

Time and location

Friday, December 08, 2023

7:30 AM - 9:30 AM Pacific Time (PT)


Marriott Marquis San Diego Marina
333 W Harbor Dr.
San Diego, California 92101

Pacific Ballroom 21-22

Danielle M. Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Deborah Stephens, DO

Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio


Registration & Breakfast: 7:00 am - 7:30 am PT

  • NCCN guidelines review for first-line and second-line regimens
  • Key variables in deciding between regimens
  • Mastering the current regimen components
    • Including MOA, key efficacy and safety data, and other considerations with BTK inhibitors, BCL-2 inhibitors, and anti-CD20 mAbs
  • Case discussions: putting it all together for effective management of CLL
  • On the horizon: MRD, CAR T-cell therapy, and noncovalent BTK inhibitors
  • ASH 2023 CLL abstract highlight: review of key studies to be presented at ASH


Venue Name

Marriott Marquis San Diego Marina


Marriott Marquis San Diego Marina
333 W Harbor Dr.
San Diego, California 92101

Room Name

Pacific Ballroom 21-22


Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia (CLL). 

Target Audience
This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration the regimen’s toxicity profile, prognostic variables, comorbidities, duration, and patient preference
  • Plan an individual treatment approach including sequence of therapy for relapsed/refractory CLL/SLL to optimize clinical benefit and quality of life in alignment with patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target 
  • Evaluate emerging strategies such as measurable residual disease (MRD; often referred to as minimal residual disease), non-covalent reversible BTKis, allogeneic hematopoietic cell transplant (HCT), and chimeric antigen receptor (CAR) T-cell therapy


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 2.0 contact hours. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-0000-23-095-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Attention Pharmacists:
Attention Pharmacists: You must complete the evaluation within 30 days of the activity for continuing pharmacy education credit to be reported to the CPE Monitor. Be sure to enter your NAPB e-profile ID and date of birth when prompted in the evaluation or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID. 

Physician Assistant/Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 


Provided by the National Comprehensive Cancer Network (NCCN) in partnership with Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Contact Information

For customer support please click here.

Mailing Address:

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.